Other News To Note
Monday, February 28, 2011
Ipsen SA, of Paris, and BioMérieux SA, of Marcy l'Etoile, France, said they will collaborate to leverage Ipsen's portfolio of compounds and BioMérieux's diagnostic tests and identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors and pituitary tumors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.